BFRA News and Press, Biofrontera AG From 08/19/21

Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021. K ey fi...

Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday...

Biofrontera has filed to raise $25 million in an IPO. The firm sells licensed treatments for skin conditions due to overexposure to the sun. BFRI appears to be rebounding from a drop in sales during the 2020 pandemic period. For further details see: Biofrontera Pursues S...

Leverkusen, Germany, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of July 2021. The Company ...

Biofrontera (BFRA) pops 6.6% premarket after its wholly owned subsidiary signed an exclusive license and supply agreement with Germany-based Medac Gesellschaft für klinische Spezialpräparate mbH for the marketing of both Ameluz and BF-RhodoLED in Poland. Under th...

Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply...

Biofrontera Inc. is presently a wholly owned U.S. subsidiary of Biofrontera AG (BFRA). The company sells FDA-approved photodynamic therapy and topical antibiotics as an exclusive licensee. The company has exclusive license to market additional indications. For further detail...

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities for capital raises were being evaluated including a potential initial public offering ("IP...

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021. The Company ...

Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. In February and March 2021, the Com...